Cena / výnosy spoločnosti Genocea Biosciences Inc
Aká je hodnota metriky Cena / výnosy spoločnosti Genocea Biosciences Inc?
Hodnota metriky Cena / výnosy spoločnosti Genocea Biosciences Inc je 0.07
Aká je definícia metriky Cena / výnosy?
Cena / výnosy (Price to sales ratio) ukazateľ predstavuje cenu spoločnosti v porovnaní s výškou jej tržieb.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Cena / výnosy spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Genocea Biosciences Inc
Čomu sa venuje spoločnosť Genocea Biosciences Inc?
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Firmy s metrikou cena / výnosy podobnou spoločnosti Genocea Biosciences Inc
- Hodnota metriky Cena / výnosy spoločnosti CESC je 0.07
- Hodnota metriky Cena / výnosy spoločnosti Pivot Technology Solutions je 0.07
- Hodnota metriky Cena / výnosy spoločnosti Flexituff Ventures International je 0.07
- Hodnota metriky Cena / výnosy spoločnosti Dorel Industries je 0.07
- Hodnota metriky Cena / výnosy spoločnosti Conduity Capital Plc je 0.07
- Hodnota metriky Cena / výnosy spoločnosti UniVision Engineering je 0.07
- Hodnota metriky Cena / výnosy spoločnosti Genocea Biosciences Inc je 0.07
- Hodnota metriky Cena / výnosy spoločnosti North Asia Strategic je 0.07
- Hodnota metriky Cena / výnosy spoločnosti Redsun Properties je 0.07
- Hodnota metriky Cena / výnosy spoločnosti United Natural Foods je 0.07
- Hodnota metriky Cena / výnosy spoločnosti Vintana Plc je 0.07
- Hodnota metriky Cena / výnosy spoločnosti Wai Chun Bio-Technology je 0.07
- Hodnota metriky Cena / výnosy spoločnosti Farm Pride Foods je 0.07